Follow
Wishrawana Sarathi Ratnayake, M.S., Ph.D
Wishrawana Sarathi Ratnayake, M.S., Ph.D
Postdoctoral Scientist, University of South Florida
Verified email at mail.usf.edu - Homepage
Title
Cited by
Cited by
Year
Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while inducing apoptosis
WS Ratnayake, AH Apostolatos, DA Ostrov, M Acevedo-Duncan
International Journal of Oncology 51 (5), 1370-1382, 2017
362017
Oncogenic PKC-ι activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors
WS Ratnayake, CA Apostolatos, AH Apostolatos, RJ Schutte, MA Huynh, ...
Cell adhesion & migration 12 (5), 447-463, 2018
322018
Inhibition of atypical protein kinase C‑ι effectively reduces the malignancy of prostate cancer cells by downregulating the NF-κB signaling cascade
AH Apostolatos, WS Ratnayake, H Win-Piazza, CA Apostolatos, ...
International Journal of Oncology 53 (5), 1836-1846, 2018
252018
Atypical PKCs activate Vimentin to facilitate prostate cancer cell motility and invasion
WS Ratnayake, CA Apostolatos, S Breedy, CL Dennison, R Hill, ...
Cell Adhesion & Migration 15 (1), 37-57, 2021
162021
FOXO1 regulates oncogenic PKC-ι expression in melanoma inversely to c-Jun in an autocrine manner via IL-17E and ICAM-1 activation
WS Ratnayke, CA Apostolatos, S Breedy, AH Apostolatos, ...
World Academy of Sciences Journal 1 (1), 25-38, 2019
92019
Preclinical testing of 5-amino-1-((1R, 2S, 3S, 4R)-2, 3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide: A potent protein kinase C-ι inhibitor as a potential prostate …
AH Apostolatos, CA Apostolatos, WS Ratnayake, A Neuger, S Sansil, ...
Anti-Cancer Drugs 30 (1), 65-71, 2019
82019
Atypical protein kinase c inhibitors can repress epithelial to mesenchymal transition (type III) in malignant melanoma
WS Ratnayake, M Acevedo-Duncan
Cancer Research 77 (13_Supplement), 862-862, 2017
82017
Use of ACPD and ICA-1 as inhibitors of atypical proteinkinase C-zeta (ζ) and iota (ι) in metastasized melanoma cells
WS Ratnayake, M Acevedo-Duncan
Cancer Research 76 (14_Supplement), 4569-4569, 2016
72016
Atypical protein kinase Cs in melanoma progression
WS Ratnayake, CA Apostolatos, M Acevedo-Duncan
Cutan Melanoma, 2019
32019
Transcription activators that regulate PKC-iota expression and are downstream targets of PKC-iota
AH Apostolatos, WS Ratnayake, T Smalley, A Islam, M Acevedo-Duncan
Cancer Research 77 (13_Supplement), 2369-2369, 2017
32017
Method of treating melanoma using an inhibitor of an atypical protein kinase C
ME Acevedo-Duncan, W Ratnayake, DA Ostrov
US Patent 10,918,650, 2021
22021
c‑Jun and FOXO1 mediate the expression of oncogenic PKC‑ι in human prostate cancer cells with an interplay between NF‑κB, IL‑8 and ICAM‑1
MAD Wishrawana S. Ratnayake, Christopher A. Apostolatos, Sloan Breedy
World Academy of Sciences Journal 2 (5), 2020
22020
Vimentin is a novel PKC-ι target facilitating migration and invasion in melanoma
WS Ratnayake, S Breedy, C Apostolatos, R Hill, C Dennison, ...
Cancer Research 79 (13_Supplement), 2857-2857, 2019
22019
Role of oncogenic protein kinase C-iota in melanoma progression; a study based on atypical protein kinase-C inhibitors
WSB Ratnayake
University of South Florida, 2019
22019
14-3-3 and Smad2/3 are crucial mediators of atypical-PKCs: Implications for neuroblastoma progression
S Breedy, WS Ratnayake, L Lajmi, R Hill, M Acevedo-Duncan
Frontiers in Oncology 13, 1051516, 2023
12023
Dual inhibition of atypical PKC signaling and PI3K/Akt signaling dysregulates c-Myc to induce apoptosis in clear cell Renal Cell Carcinoma
KM Khalid, WS Ratnayake, CA Apostolatos, M Acevedo-Duncan
Frontiers in Oncology 13, 2023
12023
Inhibition of atypical PKC signaling enhances the sensitivity of glioblastoma cells towards Temozolomide therapy
A Dey, R Patel, T Smalley, WS Ratnayake, A Islam, M Acevedo-Duncan
Cancer Research 79 (13_Supplement), 244-244, 2019
12019
PKC-ι and PKC-ζ are heavily responsible of up-regulating epithelial-mesenchymal transition (EMT) and activating Vimentin to facilitate cellular motility in prostate cancer cell …
WS Ratnayake, C Apostolatos, S Breedy, R Hill, C Dennison, ...
Cancer Research 79 (13_Supplement), 1044-1044, 2019
12019
c-Jun and FOXO1 play key roles in the overexpression of oncogenic PKC-ι in human prostate and melanoma cell lines
AH Apostolatos, WS Ratnayake, A Islam, C Apostolatos, T Smalley, ...
Cancer Research 78 (13_Supplement), 2542-2542, 2018
12018
Oncogenic protein kinase Cι drives melanoma cell epithelial-mesenchymal transition by activating vimentin through Par6/RhoA signaling
WS Ratnayake, AH Apostolatos, CA Apostolatos, A Dey, R Patel, ...
Cancer Research 78 (13_Supplement), 2022-2022, 2018
12018
The system can't perform the operation now. Try again later.
Articles 1–20